Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Net Income towards Common Stockholders (2016 - 2026)

Sunshine Biopharma filings provide 12 years of Net Income towards Common Stockholders readings, the most recent being -$2.1 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 0.8% to -$2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.0 million, a 6.9% increase, with the full-year FY2025 number at -$6.0 million, down 16.39% from a year prior.
  • Net Income towards Common Stockholders hit -$2.1 million in Q4 2025 for Sunshine Biopharma, down from $295951.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $667116.0 in Q4 2021 to a low of -$23.5 million in Q4 2022.
  • Median Net Income towards Common Stockholders over the past 5 years was -$1.4 million (2022), compared with a mean of -$2.8 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 3624.47% in 2022 and later soared 124.71% in 2025.
  • Sunshine Biopharma's Net Income towards Common Stockholders stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then grew by 0.8% to -$2.1 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$2.1 million (Q4 2025), $295951.0 (Q3 2025), and -$3.0 million (Q2 2025) per Business Quant data.